Novo Nordisk Targets Smart Insulin, Stem Cell-Therapies
Its CEO Sees Glucose-Responsive Insulin Trials ‘Within Two Years’
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.
